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Summary  1 
This study investigated the effects of fermentation conditions on the production of angiotensin-2 
converting enzyme inhibitory (ACE-I) peptide in yogurt by Lactobacillus helveticus 881315 3 
(L. helveticus) in the presence or absence of Flavourzyme®, which is derived from a mold 4 
Aspergillus oryzae and used for protein hydrolysis in various industrial. Optimal conditions for 5 
peptides with the highest ACE-I activity were 4% (v/w) inoculum size for 8 h without 6 
Flavourzyme® supplementation, and 1% inoculum size for 12 h when combined with 7 
Flavourzyme®. The yogurt fermented by L. helveticus resulted in IC50 values (concentration of 8 
inhibitor required to inhibit 50% of ACE activity under the assayed conditions) of 1.47 ± 0.04 9 
and 16.91 ± 0.25 mg/mL with and without Flavourzyme®, respectively. Seven fractions of 10 
ACE-I peptide from the yogurt incorporated with L. helveticus and Flavourzyme® were 11 
separated using the preparative high-performance liquid chromatography. Fraction (F3) 12 
showed the highest ACE-I activity with an IC50 of 35.75 ± 5.48 μg/mL. This study indicates 13 
that yogurt may be a valuable source of ACE-I peptides, which may explain the outcomes 14 
observed in the experimental and clinical studies and foresee the application of fermented milk 15 
proteins into functional foods or dietary supplements. 16 
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Yogurt is generally made from milk by mixed cultures, including two types of homo-2 
fermentative bacteria, Streptococcus thermophilus (S. thermophilus) and Lactobacillus 3 
delbrueckii subsp. bulgaricus (L. bulgaricus) (Radke-Mitchell & Sandine, 1986; De 4 
Brabandere & De Baerdemaeker, 1999). Lactobacillus helveticus (L. helveticus), is a lactic acid 5 
bacterium (LAB) and is used for the production of fermented milk beverages and some types 6 
of hard cheeses (Griffiths & Tellez, 2013). In previous studies, fermented milk with L. 7 
helveticus exhibited anti-hypertensive effect in both animal and clinical studies due to its 8 
angiotensin-converting enzyme inhibitory (ACE-I) activity (Chen et al., 2014; Jauhiainen et 9 
al., 2005; Aihara et al., 2005; Griffiths & Tellez, 2013). Angiotensin-converting enzyme 10 
(ACE), as a part of the renin-angiotensin system, has an important role in the regulation of 11 
blood pressure by converting angiotensin-І into a potent vasoconstrictor, angiotensin-II. 12 
Angiotensin-II induces the release of aldosterone and therefore increases the sodium retention 13 
and blood pressure (Muro Urista et al., 2011). Thus, inhibition of ACE can lower the blood 14 
pressure, and has potential health benefits to hypertensive patients (Tuomilehto et al., 2004; 15 
Aihara et al., 2005). The renin-angiotensin system has therefore become a key target for anti-16 
hypertensive drugs (Miura et al., 2011), however, conventional drugs targeting this system 17 
cause various adverse effects, such as headache, dizziness and cough (Soleimani et al., 2015; 18 
Coulter D, 1987). 19 
Anti-hypertensive peptides isolated from fermented dairy products such as fermented milk 20 
drink and cheese could represent a healthier and natural alternative for the ACE-I drugs as a 21 
non-pharmacological therapy to reduce the risk of hypertension (Hannu & Anne, 2006; 22 
Minervini et al., 2003; Pan & Guo, 2010; Donkor et al., 2007b). Previous studies showed that 23 
two tripeptides [Val-Pro-Pro (VPP), Ile-Pro-Pro (IPP)] released from fermented milk by 24 
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several types of L. helveticus strains exhibited anti-hypertensive peptide effects due to high 1 
ACE-I activity in both human (Tuomilehto et al., 2004; Ishida et al., 2011; Cicero et al., 2013) 2 
and rats (Chen et al., 2014; Jauhiainen et al., 2010). However, little information is available on 3 
whether yogurt is a better source of ACE-I peptides when it is further fermented by L. 4 
helveticus strains.  5 
During yogurt fermentation, bacteria growth and product synthesis depend on medium 6 
compositions and culture conditions such as temperature, pH, inoculum size and fermentation 7 
duration and so on (Agyei et al., 2012). Inoculum size was an important factor for the growth 8 
rate of the bacterial culture. When the inoculum size is too low, it would take longer for bacteria 9 
to reach the logarithmic growth phase (Min et al., 2013). In contrast, a greater inoculum size 10 
could result in a quick consumption of nutrients required by bacterial strains, thus fermentation 11 
could be interrupted (Min et al., 2013). The optimisation of various fermentation parameters 12 
for maximising active peptide production by LAB is therefore a major research endeavour. 13 
Supplementation of some enzymes with strong proteolytic activity is alternative method to 14 
improve functional peptide production during yogurt fermentation (Donkor et al., 2007a; 15 
Shabboo & Ahmad, 2011). Among of these enzymes, Flavourzyme® is an important 16 
contributor to hydrolyse milk protein for the production of ACE-I peptides (Tsai et al., 2008). 17 
Flavourzyme® contains enzymes that are generally recognized as safe for use in the food 18 
industry (Boschin et al., 2014). It is derived from a mold Aspergillus oryzae and used for 19 
protein hydrolysis in various industrial and research applications due to its high endoprotease 20 
and exopeptidase activities (Merz et al., 2015).. Ahtesh et al. (2016 a, b) reported that 21 
Flavourzyme® can be used to increase the hydrolysis of the milk protein into further small 22 
molecular weight ACE-I peptides in 12% of reconstituted skim milk (RSM). However, the 23 
role of Flavourzyme® in the production of bioactive peptides from yogurt is not well 24 
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reported.  Therefore, the aim of this study was to determine the optimal fermentation 1 
conditions for the production of ACE-I peptides from yogurt fermented by Lactobacillus 2 
strains. Furthermore, we investigated whether the inclusion of Flavourzyme® is able to 3 
increase the release of ACE-I peptides in yogurt media.   4 
Material and Methods  5 
Culture medium and reagents 6 
Glycerol de Man, Rogosa, Sharpe (MRS) broth was purchased from Oxoid, Ltd., West 7 
Heidelberg, Victoria, Australia. Reconstituted skim milk (RSM) powder (52% lactose, 37% 8 
protein, 8.6% ash, and 1.2% fat) was obtained from Woolworths Ltd, Australia. M17 broth was 9 
purchased from Oxoid, Ltd, Hampshire, England. Flavourzyme® (EC 3.4.11.1, an amino 10 
peptidase with an activity of 500 Leucine Amino-peptidase per gram), hippuryl-L-histidyl-L-11 
leucine (HHL), ACE enzyme (from rabbit lung, 0.1 UN) and hippuric acid (HA) were 12 
purchased from Sigma-Aldrich Pty. Ltd., NSW Australia.  13 
Bacteria storage and propagation 14 
Lactobacillus helveticus ASCC 881315 (L. helveticus), Streptococcus thermophiles ASCC 15 
1275 (S. thermophiles) and Lactobacillus delbrueckii subsq. bulgaricus 1466 (L. bulgaricus) 16 
were obtained from Dairy Innovation Australia Ltd, Werribee, Victoria, Australia. The L. 17 
helveticus strain was stored in MRS broth, while S. thermophiles and L. bulgaricus strains were 18 
kept in RSM at −80 °C. For activation of these strains, 100 µL of L. helveticus and L. bulgaricus 19 
strains were transferred separately into 9.9 mL of 40% MRS broth, whereas S. thermophiles 20 
was activated via transfer of 100 µL to 9.9 ml of 3.7% M17 broth, containing 0.5% lactose. All 21 
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media were autoclaved at 121 °C for 15 minutes before use. Following activation, all strains 1 
were incubated at 37 °C for 24 h  2 
Yogurt preparation   3 
Yogurt was prepared by dissolving skim milk powder (12%, w/w) in distilled water. RSM was 4 
heated to 90 °C for 30 min, then inoculated with 1% activated S. thermophiles and L. bulgaricus 5 
cultures (1: 1 of ratio) and fermented at 42 °C for 6 hours to produce yogurt. Then the 6 
fermentation process was stopped by cooling at 4 °C overnight. 7 
Release of bioactive peptides from yogurt  8 
L. helveticus 881315 strain was incorporated into yogurt with or without Flavourzyme® 9 
(0.14%). Specifically, the yogurt was re-incubated at 37 °C with stirring (200 rpm) for the 10 
purpose of a better homogenization between yogurt and Flavourzyme® during 16 h. After 11 
incubation for 4, 8, 12 and 16 h, with different inoculum sizes of L. helveticus (1%, 2%, 3% 12 
and 4% v/w), samples were taken for analysis. The fermentation process was terminated by 13 
heating the yogurt at 90 °C for 20 min to stop enzyme activity. Subsequently, 25 mL of yogurt 14 
sample was centrifuged at 4000 × g at 4 °C for 30 min to separate proteins. The supernatant 15 
containing soluble peptides was freeze-dried (Freeze-drier, John Morris Scientific Pty Ltd, 16 
Australia) for 72 h. The freeze-dried peptides powder was stored at -20 °C for analysis. 17 
Determination of ACE-Inhibitory activity  18 
20 mg of the freeze-dried peptide powder from normal yogurt with starter culture or yogurt 19 
incorporated with L. helveticus without Flavourzyme® was dissolved in 1 mL of Tris buffer 20 
(50 mM, pH 8.3) containing 300 mM sodium chloride, respectively. However for the peptides 21 
from yogurt incorporated with L. helveticus and Flavourzyme®, 2.5 mg/mL of powder was 22 
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dissolved in the same Tris buffer, as these peptides showed 100% ACE-I activity, when the 1 
concentration was 20 mg/mL; therefore, lower concentration (2.5 mg/mL) was used to assess 2 
the production of ACE-I peptides under different fermentation conditions. 3 
 To determine the peptide fractions from yogurt in the presence of Flavourzyme®, freeze-dried 4 
powder (2.5 mg) was dissolved in Tris buffer (50 mM, pH 8.3) containing 300 mM sodium 5 
chloride to prepare the sample solutions of 62.5, 125, 250, and 500 µg/mL concentrations to 6 
calculate IC50 value of different fractions. The IC50 value was defined as the concentration of 7 
inhibitor required to inhibit 50% of ACE activity under the assayed conditions. 8 
Evaluation of ACE-I activity was assayed using a reversed-phase HPLC system (RP-HPLC, 9 
from Varian Analytical Instruments, Santa Clara, CA, USA) previously described by Donkor 10 
et al 2007a. It is based on the hydrolysis HHL by ACE to hippuric acid (HA) and histidyl-11 
leucine (HL) as products. The HA released from HHL is directly related to the ACE activity. 12 
ACE enzyme and HHL was prepared in Tris buffer. Briefly, the assay consisted of 300 µL of 13 
3.0 mM HHL, 300 µL of 3.0 mU ACE enzyme, and 300 µL of peptide solution. The mixture 14 
was placed in a glass tube and then incubated at 37 °C in a water bath for 0.5 h, mixed for 1 15 
min, then returned to the water bath for another 0.5 h. The reaction was stopped by heating the 16 
mixture in an 85 °C water bath for 10 min in order to inactivate enzymes. The reaction mixture 17 
was stored at -20 °C before further analysis of released hippuric acid by RP- HPLC.  18 
HA standard curve was prepared in five different concentrations (5, 10, 15, 20 and 25 µg/mL). 19 
The isocratic mobile phase composition was optimized to 12.5% acetonitrile (Merck) in MilliQ 20 
water (v/v) containing 0.1% trifluoroacetic acid (TFA), which was filtered (0.45 μm) prior to 21 
running through the column. The temperature of the column was kept at room temperature (~22 22 
°C).  An aliquot (10 µL) of the mixture was injected onto a VyDAC® C18 300 Å (250 mm x 23 
4.6 mm, 5 µm) column (Grace Vydac, Hesperia CA, USA) using a Varian HPLC equipped 24 
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with an auto sampler. The flow rate was set at 0.6 mL/min. The quantitative estimation of HA 1 
present was determined using a calibration curve of standard HA using a UV detector set at 2 
228 nm. 3 
The percent of ACE inhibition was calculated as follows: 4 
ACE inhibition (%) = C (control) − C (sample)C (control)  × 100 5 
Where: C (control) was the concentration of HA without the tested samples (active peptides), 6 
which contained  300 µL of HHL, 300 µL of ACE enzyme and 300 µL of Tris buffer, and C 7 
(sample) was the concentration of HA with the tested samples, which contained 300 µL of 8 
HHL, 300 µL of ACE enzyme and 300 µL of peptide solution.  9 
Peptide profile of water-soluble extract 10 
The RP-HPLC assay was developed for the profile of water-soluble peptides extracted from 11 
yogurt as control, and yogurt containing L. helveticus strain with or without Flavourzyme®, 12 
respectively (Nielsen et al., 2009). The freeze-dried peptide powder (20 mg) was dissolved in 13 
1 mL of 0.1% TFA in distilled water. All the supernatants thus obtained were filtered through 14 
a 0.45 μm membrane filter and stored at –20 °C until assayed. Water soluble peptides were 15 
profiled by a RP- HPLC (SHIMADZU Corporation, Japan) using C-18 monomeric column (5 16 
μm, 300 Å, 250 mm x 4.6 mm; Grace Vydac, Hesperia CA, USA). The injection volume was 17 
10 μL. Solvent A was a mixture of water with 0.1% TFA (v/v) and solvent B contained 18 
acetonitrile with 0.1% TFA (v/v). Active peptides were eluted with a linear gradient of solvents 19 
B in A at concentrations from 0 to 100% over 30 min at a flow rate of 0.75 mL/min. The elution 20 
profile was monitored at 215 nm by UV-Vis detector at room temperature (~22 °C).  21 
Peptide fractions  22 
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Bioactive peptide fractions from yogurt with L. helveticus and Flavourzyme® were collected 1 
using a column (Prep Nova-Pack HR C18, 60 Å, 250 mm x 10 mm, 10 µm, Phenomenex, Pty 2 
Ltd, Australia) by preparative RP-HPLC. Solvent A was a mixture of water and TFA (1000:1, 3 
v/v), and solvent B contained acetonitrile and TFA (1000:1, v/v). The injection volume was 1 4 
mL with 20 mg/mL of yogurt peptides. The peptides were eluted with a linear gradient of 5 
solvent B in A ranged from 0% to 40% over 90 min, at a flow rate 4 mL/min. Detection was 6 
carried out at 215 nm by UV-Vis detector. According to the retention time of peaks, 7 fractions 7 
were collected at 10 min for fraction F2, F3, F4 and F7, 12 min for F1, and 14 min for F5 and 8 
F6, respectively. All fractions were frozen dried under vacuum. IC50 of ACE activity was 9 
determined for each fraction. 10 
Statistical analysis 11 
All results are expressed as mean ± standard deviation for each measurement (n = 3), including 12 
yogurt fermentation, the pH, determination of ACE-I activity and calculation of the IC50 value. 13 
The yogurt fermentation was carried out in two separate procedures. The first was focused on 14 
the four fermentation times (4, 8, 12 and 16 h) with 1% inoculum sizes of L. helveticus. The 15 
second was performed with different inoculum sizes of L. helveticus (1%, 2%, 3% and 4% 16 
v/w), after the optimal fermentation time was determined. One-way ANOVA was performed 17 
using software SPSS version 22 (IBM Chicago, IL, USA) to analyse the significant differences 18 
in the treatments, which were fermentation time, inoculum sizes and presence or absence of 19 
Flavourzyme®. Fisher’s (least significant difference; LSD) test was used to differentiate 20 
significant differences among the treatments. P < 0.05 was considered as significant. 21 
Results and Discussion 22 
Effects of L. helveticus strains and Flavourzyme® on the pH  of yogurt  23 
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The pH of yogurt containing L. helveticus strain with or without Flavourzyme® with different 1 
fermentation time and inoculation volume is shown in Figure 1. The pH of yogurt fermented 2 
by S. thermophiles and L. bulgaricus was 4.71 ± 0.04. The pH was decreased to 4.45 ± 0.04 3 
when L. helveticus strains were incorporated alone into the yogurt at 37 °C for 16 h (P < 0.05; 4 
Figure 1A). The pH was further decreased to 4.06 ± 0.03 when Flavourzyme® and L. helveticus 5 
strains were added in the yogurt for 16 h of fermentation (P < 0.01; Figure 1A). The decrease 6 
of the pH could be due to the production of lactic acid by lactic acid bacteria strains (Donkor 7 
et al., 2007a). The pH of yogurt in the presence of Flavourzyme® was significantly lower than 8 
that without Flavourzyme® for the same fermentation time (P < 0.01; Figure 1A). The presence 9 
of Flavourzyme® could result in higher proteolysis and the release of more peptides, which was 10 
further supported by the experimental data on the fermentation time and peptides of ACE-I due 11 
to further hydrolysis of milk protein by Flavourzyme® to small size molecular weight of 12 
peptides (Fatah et al., 2016a; Fatah et al., 2016b). Previous research has demonstrated the same 13 
trends using these L. helveticus strains in the 12 h fermentation of skim milk and the pH of the 14 
fermented product was 3.4 when Flavourzyme® was added compared with 5.0 without addition 15 
of Flavourzyme® (Fatah et al., 2016b). In the same study, it was also reported that the growth 16 
of all strains of L. helveticus, when mixed with Flavourzyme®, was increased significantly at 8 17 
h and declined after 8 h of fermentation at pH 3.4. This was possibly due to the low pH and 18 
heat treatment reducing available nutrients for growth (Fatah et al., 2016b; Dissanayake et al., 19 
2013). The reason for the higher pH (4.15) in the present study may be attributed to the type of 20 
media. In this study, yogurt was used as a media while RSM was used in the study by Ahtesh 21 
et al (2016b). 22 
In the fermentation of yogurt, the pH decreases steadily in correspondence with the milk 23 
acidification (two homofermentative bacteria transform fermented (milk) sugar into lactic acid) 24 
that underlies the fermentation process (De Brabandere & De Baerdemaeker, 1999). Many 25 
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factors including starter culture, heat treatment, fermentation time, inoculum size and 1 
incubation temperature, affect the pH in yogurt fermentation. In this study, the decrease in pH 2 
was observed in yogurt combined with different inoculum size of L. helveticus (P < 0.01; 3 
Figure 1B). After fermentation, the pH of yogurt decreased to 3.91 ± 0.04 without 4 
Flavourzyme®, and 4.00 ± 0.03 with Flavourzyme® (P < 0.05; Figure 1B). The pH was lower 5 
with 1% inoculum of L. helveticus with Flavourzyme® than those without Flavourzyme® in the 6 
same inoculum size of L. helveticus (P < 0.01; Figure 1B). Then there were no significant 7 
changes with the increase of inoculum size of L. helveticus in the presence of Flavourzyme®. 8 
However, the pH declined with the increase of inoculum size of L. helveticus in absence of 9 
Flavourzyme®. 10 
Effect of fermentation time on ACE-I activity with or without 11 
Flavourzyme® 12 
A time course of peptide production showed that ACE-I activity of peptides was significant 13 
difference between the groups with and without Flavourzyme® at the same fermentation time 14 
(P < 0.01; Figure 2A). The results demonstrate that ACE-I activity increased gradually with 15 
the fermentation time, when Flavourzyme® was supplemented during yogurt fermentation. 16 
Specifically, ACE-I activity in the absence of Flavourzyme® group increased significantly from 17 
13.0 ± 1.8 % to 50.8 ± 3.3% (20 mg/mL) during 8 h fermentation, then mildly decreased at 12 18 
h fermentation (46.0 ± 0.9%, P = 0.12; Figure 2A), but increased again with by 16 h 19 
fermentation back to similar levels seen at 8 h fermentation (51.4 ± 0.2%, P = 0.81; Figure 20 
2A). These may be associated with the hydrolysis of ACE-I peptides, and the hydrolysed 21 
peptides can then be transported  across the cell membrane of bacteria by several transporters 22 
(Law & Haandrikman, 1997). Similar results were reported by Pan & Gao (2010) who showed 23 
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that the optimal fermentation time to produce ACE-I activity from fermented sour milk was 8 1 
h (Pan & Guo, 2010).  2 
A similar trend in ACE-I activity dependence to fermentation time was noted in the presence 3 
of Flavourzyme®, compared with the absence of Flavourzyme® (Figure 2A). The results 4 
showed that in the presence of Flavourzyme®, ACE-I activity increased gradually and reached 5 
the highest level in 12 h fermentation (86.5 ± 0.5% at concentration of 2.5 mg/mL) (P < 0.05; 6 
Figure 2A). It then decreased after an additional 4 h fermentation (P < 0.05; Figure 2A). These 7 
results suggest that 12 h incubation was the optimal fermentation time to produce anti-8 
hypertensive peptides from yogurt, in combination with Flavourzyme®. These studies indicate 9 
that Flavourzyme® allows reaching high concentrations in ACE-I peptides in a short 10 
fermentation time, contrarily to formulation without Flavourzyme®. This was also confirmed 11 
by the change of pH levels in the presence or absence of Flavourzyme® (4.06 ± 0.03 and 4.42 12 
± 0.02, respectively, Figure 1). In agreement with this result, a previous study showed that 13 
ACE-I reached the highest level (approximate 70%) at 12 h fermentation of RSM by L. 14 
helveticus strain 881315 without Flavourzyme® addition; however, more than 70% ACE-I 15 
activity was obtained after only 4 h fermentation by the same strain with the supplementation 16 
of Flavourzyme® (Fatah et al., 2016b). 17 
Effect of inoculum size on ACE-I activity with or without Flavourzyme® 18 
Figure 2B shows the effects of inoculum size of L. helveticus strains on ACE-I activity with or 19 
without Flavourzyme® in yogurt. Generally, the results showed a significant difference 20 
between the groups with and without Flavourzyme® in the same level of inoculum size (P < 21 
0.01; Figure 2B). ACE-I activity increased gradually with increased inoculum size without 22 
Flavourzyme®. L. helveticus strains (4%) in the yogurt exhibited the highest ACE-I activity, 23 
with 59.2 ± 0.9% at 20 mg/mL of the hydrolysate, for optimal fermentation time of 12 h (P < 24 
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0.05; Figure 2B). It has been shown that 4% of inoculum size produced ACE-I activity in sour 1 
milk fermented by L. helveticus LB10,  possibly due to the high cell-envelope proteinase 2 
activity (Pan & Guo, 2010), which may have also occurred in the present study.  3 
It was found that, with the same inoculum size, ACE-I can be improved significantly when 4 
combined with Flavourzyme® (P < 0.01; Figure 2B). The highest ACE-I (86.5% at 5 
concentration of 2.5 mg/mL) was obtained with 1% of L. helveticus plus Flavourzyme® 6 
following a 12 h fermentation (P < 0.01; Figure 2B). Then, ACE-I activity showed slight 7 
decrease with increasing inoculum size. ACE-I activity of peptides reduced to 82% with 4% of 8 
L. helveticus combined with Flavourzyme®, however this is still higher than those in the 9 
absence of Flavourzyme® (59.17 ± 0.88%). 10 
ACE-inhibition activity 11 
There were significant differences in ACE-I activity between yogurt with starter culture and 12 
yogurt with addition of L. helveticus and/or Flavourzyme®. Peptides from yogurt showed the 13 
lowest activity of ACE-I, which was only 33.1 ± 2.7% at the concentration of 20 mg/mL (P < 14 
0.01; Figure 3). In contrast, ACE-I activity was increased to 59.2 ± 0.9%, when L. helveticus 15 
strain was added to the yogurt at 37 °C for 12 h (P < 0.01; Figure 3). Furthermore, a 100% 16 
inhibition was observed when both L. helveticus strain and Flavourzyme® were added to the 17 
yogurt ® (Figure 3). 18 
The IC50 value is an important indicator to assess the ACE-I potential. It can be used to classify 19 
individual bioactive peptides from different fermentation products based on their ACE-I 20 
capacity in vitro. In this study, the IC50 value of yogurt only fermented by starter cultures (30.45 21 
± 2.32 mg/mL) showed the lowest effect on ACE-I (P < 0.01; Figure 3). The hydrolysate 22 
extracted yogurt incorporated with L. helveticus strains demonstrated lower IC50 (16.91 ± 0.25 23 
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mg/mL), compared with yogurt without these strains (P < 0.01; Figure 3), which supported that 1 
L. helveticus has a potential to hydrolyse protein from yogurt and produce anti-hypertensive 2 
peptides. In yogurt supplemented with Flavourzyme®, significantly more ACE-I peptides were 3 
released with an IC50 of 1.47 ± 0.04 mg/mL, which was 20-fold higher than yogurt without L. 4 
helveticus strains, and 12-fold higher than yogurt without Flavourzyme® (P < 0.01; Figure 3). 5 
In general, the effect of peptides on ACE-I depends on several factors, such as the type of 6 
bacteria strains, media used, fermentation conditions and enzymes used. Tsai et al. (2008) 7 
reported that, in milk fermented by lactic bacteria with Flavourzyme®, more active peptides 8 
were produced to exhibit higher ACE-I activity, with an IC50 value of 0.226 mg/mL in 9 
Flavourzyme-facilitated fermentation in contrast to an IC50 value of 0.515 mg/mL in the 10 
fermentation without Flavourzyme®. The different media and fermentation condition could 11 
possibly contribute to the higher IC50 values found in study of Tsai et al. (2008), which used 12 
the mixture of 4.5% (w/v) skimmed milk powder, 5.5% (w/v) whole milk powder and 7% (w/v) 13 
sucrose as a medium that was fermented by 0.1% (w/v) of lactic acid bacteria powder. By 14 
contrast, 12% skimmed milk powder was used as a medium and it was fermented with 1% of 15 
activated lactic acid bacteria in the current study.   16 
Peptide profile of water-soluble extracts  17 
The degree of hydrolysis at the higher ACE-I activity was determined by analysis of peptides 18 
from different yogurts using RP-HPLC. The peptide profiles (20 mg/mL of the concentration) 19 
showed similar characteristics between yogurt with starter culture and yogurt incorporated with 20 
L. helveticus with or without Flavourzyme® (Figure 4). In particular, four major peaks appeared 21 
in the first eight minutes when the substantial hydrolysis took place. It was then followed by 22 
several minor peaks. Although the number of the proteolytic peptides in yogurt fermented by 23 
S. thermophiles and L. bulgaricus was almost the same as those in yogurt added with L. 24 
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helveticus based on the peptide profiles (Figure 4A, 4B), ACE-I activity in yogurt without L. 1 
helveticus was lower than that in yogurt with L. helveticus (Figure 3). Many anti-hypertensive 2 
milk peptides have been isolated and identified (Hannu & Anne, 2006). However, only specific 3 
peptides, especially those containing proline in the amino acid sequence at the C-terminal, such 4 
as VPP, IPP and LPP, have high ACE-I activity from fermented dairy products (Butikofer et 5 
al., 2008). In fermented milk, high amounts of VPP and IPP were obtained in most cases after 6 
fermentation with L. helveticus due to their higher proteolytic activity and their special 7 
capability to degrade the milk protein into these tripeptides, and also accumulate these 8 
tripeptides in the dairy products (Hu et al., 2011).  9 
Yogurt supplemented with L. helveticus and Flavourzyme® showed different peptide peaks 10 
(Figure 4C). More peaks were detected with the retention times between 3 and 18 min due to 11 
the increase in milk protein hydrolyses by Flavourzyme®, which led to the release of peptides 12 
with small molecular weight. These results were consistent with the recent study by Ahtesh et 13 
al. (2016b) using the same strains in the fermentation of 12% of RSM (Fatah et al,. 2016b. Tsai 14 
et al. (2008) indicated that Flavourzyme® has a potency to increase the content of soluble 15 
protein (10-fold) and peptides (5-fold) in milk whey fermented by lactic acid bacteria (Tsai et 16 
al., 2008).  17 
ACE-I activity of fractions 18 
In order to pinpoint the peptides bearing a potential ACE-I activity, peptides from yogurt 19 
supplemented with Flavourzyme® were separated using preparative RP-HPLC, and seven 20 
fractions (F1- F7) were collected according to the elution time. Their ACE-I activity was then 21 
determined (Figure 5). The results implied that fractions F3- F6 were primarily responsible for 22 
ACE-I activities of peptides. Among them, fraction F3 exhibited the highest activity, 23 
corresponding to an IC50 value of 35.75 ± 5.48 μg/mL, which was almost 42-fold higher than 24 
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that found in the total hydrolysate (1470 ± 40 μg/mL) (P < 0.01; Figure 5). Fraction F7 showed 1 
the lowest inhibitory effect on ACE, with an IC50 value of 2211.22 ± 213.41 μg/mL. These 2 
findings implied that some small peptides separated and collected from yogurt showed 3 
functional accumulation or synergism on ACE-I activities. 4 
Six fractions were separated and collected based on the molecular weight of peptides extracted 5 
from fermented skim milk with L. bulgaricus LB340 in the study by Qian et al (2011), which 6 
revealed that fraction F2 showed the highest ACE-I activity (66.4%) at concentration of 100 7 
mg/mL, with an IC50 value of 67.71 ± 7.62 mg/mL, which was lower compared with those in 8 
this study (Qian et al., 2011). The differences observed in ACE-I effect of peptides may be 9 
attributed to the variation in proteolytic activity of bacteria stains (L. bulgaricus LB340 versus 10 
L. helveticus 881315) and cultures (skim milk versus yogurt), and therefore the variety of 11 
peptides present in the hydrolysates. The synthetic bioactive peptides, based on purification, 12 
characterization and identification of their amino acid sequence could be potentially used to 13 
develop functional foods that are beneficial to human health. Further work is required to 14 




The bioactive peptides released from the aqueous extracts of yogurt have ACE-I activity. The 19 
optimal fermentation conditions for producing ACE-I peptides were 1% inoculum size of L. 20 
helveticus strain 881315 for 12 h combined with Flavourzyme®. The IC50 value was 1.47 ± 21 
0.04 mg/mL, which was higher than yogurt or yogurt supplemented with L. helveticus strain 22 
without Flavourzyme®. The observation of peptide profiles also confirmed different quantities 23 
17 
 
of peptides in different yogurts, and yogurt with or without Flavourzyme®. Among seven 1 
fractions of peptides, fraction F3 displayed the highest ACE-I effect. Therefore, yogurts 2 
provide a good source for the generation of bioactive peptides with ACE-I activity in fermented 3 
dairy products. Although further in vivo study is required to confirm the ACE-I activity of 4 
yogurt peptides and their potential anti-hypertensive properties, the outcomes of this study hold 5 
a promising potential as a complementary therapy for hypertension. It is necessary to identify 6 
the specific peptides in the yogurt for future development of potential functional foods.   7 
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